FDA Approves Allogeneic Cell Therapy TREGZI for GVHD; New Advanced Cell Therapy Association Launches in Europe

July 5, 2026

RegMedNet UK

Overview

The FDA has approved Orca Bio’s allogeneic cell therapy TREGZI (Orc-T®) for graft-versus-host disease (GVHD), based on positive Phase 3 Precision-T trial results, aiming to mitigate GVHD and reconstruct immunity. Simultaneously, Siren Biotechnology secured an $8 million CIRM grant for AAV immunogene therapy development for brain tumors, and a new association was established in Europe to address challenges in advanced cell therapies. Additionally, seven companies were selected for the FDA’s Manufacturing PreCheck Pilot Program. These developments signify accelerating clinical progress and a maturing regulatory and manufacturing landscape within the cell therapy sector.

In Depth

Key Findings

The FDA has granted approval for Orca Bio’s allogeneic cell therapy, TREGZI (Orc-T®), for the prevention and treatment of graft-versus-host disease (GVHD). This represents a pivotal advancement, offering a new treatment option for a major complication post-bone marrow transplantation and promising improved patient outcomes. Concurrently, a new industry association has been launched in Europe to comprehensively address the challenges faced by advanced cell therapies across the continent.

Technical / Clinical Details

TREGZI is an allogeneic cell therapy developed by Orca Bio, leveraging precise T-cell manipulation techniques. This therapy is designed to suppress the onset of GVHD following bone marrow transplantation while efficiently reconstructing the patient’s immune system. The Phase 3 Precision-T trial demonstrated a statistically significant reduction in GVHD incidence compared to standard care, alongside accelerated early immune recovery post-transplant. In a separate development, Siren Biotechnology secured an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for the clinical development of an adeno-associated virus (AAV)-based immunogene therapy targeting brain tumors. This funding is crucial for advancing gene therapy potential against challenging brain cancers. The newly established Advanced Cell Therapy Association in Europe aims to foster industry-wide collaboration and progress through a common platform, addressing complex regulatory environments, manufacturing standardization, and market access challenges. Furthermore, seven companies selected for the FDA’s Manufacturing PreCheck Pilot Program are exploring innovative manufacturing technologies and quality control methods, seeking to streamline the approval process through early engagement with regulatory authorities.

Background & Context

GVHD is a severe complication following allogeneic hematopoietic stem cell transplantation, leading to significant morbidity and mortality. Existing GVHD treatments have had limited efficacy, creating an urgent need for novel therapies. TREGZI’s approval addresses this unmet medical need and is expected to profoundly impact the entire cell therapy field as a successful example of precise cell manipulation techniques. The formation of the European association underscores the critical importance of international regulatory and manufacturing challenges in the commercialization and dissemination of cell and gene therapy products. The FDA’s Manufacturing PreCheck Program is designed to support developers in more efficiently bringing products to market by providing feedback on manufacturing processes even before the full submission of an application.

Strategic Significance & Outlook

TREGZI’s approval holds the potential to significantly alter the treatment paradigm for GVHD. Future data on its long-term efficacy and safety in broader patient populations will be keenly observed. Siren Biotechnology’s grant signals the promising potential of AAV gene therapies for difficult targets like brain tumors, and its clinical progress is highly anticipated. The new European association is poised to play a vital role in promoting the growth of the advanced cell therapy ecosystem in Europe by strengthening dialogue with regulatory bodies, sharing manufacturing expertise, and standardizing quality benchmarks. The success of the FDA’s PreCheck program could also influence other regulatory agencies globally, further optimizing the development landscape for cell and gene therapies.

Source: https://www.regmednet.com/cell-therapy-weekly-association-launches-to-address-challenges-in-advanced-cell-therapies-in-europe/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.